Interpace Biosciences, Inc. (IDXG)
1.523
-0.09
(-5.42%)
USD |
OTCM |
Aug 21, 16:00
Interpace Biosciences EPS Diluted (Quarterly) : 0.0057 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0057 |
| March 31, 2026 | 0.026 |
| December 31, 2025 | 0.8178 |
| September 30, 2025 | 0.0329 |
| June 30, 2025 | -0.1447 |
| March 31, 2025 | 0.0594 |
| December 31, 2024 | 0.3214 |
| September 30, 2024 | 0.3789 |
| June 30, 2024 | 0.5537 |
| March 31, 2024 | 0.1615 |
| December 31, 2023 | 0.2452 |
| September 30, 2023 | -0.1422 |
| June 30, 2023 | 0.0406 |
| March 31, 2023 | 0.0815 |
| December 31, 2022 | -0.3662 |
| September 30, 2022 | -3.349 |
| June 30, 2022 | -0.9314 |
| March 31, 2022 | -0.534 |
| December 31, 2021 | -0.8919 |
| September 30, 2021 | -0.855 |
| June 30, 2021 | -0.8401 |
| March 31, 2021 | -1.029 |
| December 31, 2020 | -2.014 |
| September 30, 2020 | -1.544 |
| June 30, 2020 | -1.384 |
| Date | Value |
|---|---|
| March 31, 2020 | -2.379 |
| December 31, 2019 | -2.893 |
| September 30, 2019 | -19.69 |
| June 30, 2019 | -13.91 |
| March 31, 2019 | -0.9728 |
| December 31, 2018 | -1.411 |
| September 30, 2018 | -1.078 |
| June 30, 2018 | -0.6863 |
| March 31, 2018 | -1.146 |
| December 31, 2017 | -1.863 |
| September 30, 2017 | -1.505 |
| June 30, 2017 | -6.53 |
| March 31, 2017 | 5.50 |
| December 31, 2016 | 32.36 |
| September 30, 2016 | -41.25 |
| June 30, 2016 | -13.00 |
| March 31, 2016 | -27.00 |
| September 30, 2015 | -31.00 |
| June 30, 2015 | -46.00 |
| March 31, 2015 | -26.00 |
| December 31, 2014 | -50.00 |
| September 30, 2014 | -29.00 |
| June 30, 2014 | -18.00 |
| March 31, 2014 | -11.00 |
| December 31, 2013 | -25.00 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Exlites Holdings International, Inc. | -0.0002 |
| Xcelerate, Inc. | -0.0001 |
| Vivos Therapeutics, Inc. | -0.31 |
| Hinge Health, Inc. | 0.5167 |
| PD-Rx Pharmaceuticals, Inc. | -- |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 0.266M |
| Revenue (Quarterly) | 9.131M |
| Total Expenses (Quarterly) | 8.865M |
| Enterprise Value | 40.47M |
| Gross Profit Margin (Quarterly) | 61.91% |
| Profit Margin (Quarterly) | 2.91% |
| Earnings Yield | 57.95% |
| Operating Earnings Yield | 9.87% |
| Normalized Earnings Yield | 57.75 |